Loading stock data…
Absci Corporation (ABSI)
$8.91+0.09 (+1.02%)
After Hours$9.00+0.09 (+1.01%)· Last close Sep 8
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Absci Corporation in the Healthcare sector is trading at $8.91 with a market capitalization of $926M. Wall Street consensus targets $13.89 (9 analysts), implying a +55.9% move over the next 12 months. The stock is currently 26% below its 52-week high of $12.05, remaining 67.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +55.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $215,000↓ | $650,000↑ | $378,000↓ | $593,000↓ | $1.18M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.85M↑ | -$36.14M↓ | -$30.15M↑ | -$31.39M↓ | -$27.73M |
| Net Income | -$29.60M↓ | -$29.56M↓ | -$28.71M↑ | -$30.57M↓ | -$26.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bow...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$926.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.87%
Volume
Today's trading volume
2.50M
Recent News
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
Hair loss biotechs Veradermics, Absci, and Cosmo are drawing investor bets on a market untouched since the 1990s.
Absci (ABSI) Q2 2026 Earnings Call Transcript
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal.
AMD’s $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next
AMD just filed its first-ever 13F, and buried inside a $1.31 billion portfolio are five positions that trace exactly where the company believes AI infrastructure spending lands next, including one ticker most investors will never think to check.
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.